Diagnosis & Therapy

Lupus patients at high risk for adverse reactions to PCP antibiotic prophylaxis

Patients with systemic lupus erythematosus (SLE) who take trimethoprim-sulfamethoxazole (TMP-SMX) prophylactically to ward against the life-threatening fungal infection pneumocystis carinii pneumonia (PCP), seen in patients who are on high-dose glucocorticoids or immunosuppressants, had more than double the likelihood for adverse drug reactions (ADRs) when compared with patients with other connective tissue diseases, according to findings from a study presented at the virtual annual meeting of the American College of Rheumatology.
Read More

Hydroxychloroquine use lessens AFib risk in lupus patients

A new study has found that the use of hydroxychloroquine in patients with systemic lupus erythematosus (SLE) greatly decreased their risk of incident atrial fibrillation (AFib).

Read More

MMF forever? Stopping appears safe for some with lupus

A randomized trial finds that, among patients achieving quiescence after long-term MMF therapy, the probability of serious flares over more than a year was low and similar, regardless of whether patients stopped or continued the drug.

Read More

A rheumatologist’s perspective on the community impact of hydroxychloroquine shortages

Anxiety rose in the lupus community as new data surfaced that COVID-19–positive patients treated with hydroxychloroquine were experiencing significant side effects. The one medication I would typically describe as low risk was suddenly high risk.

Read More

Increasing minority representation in lupus trials proves as multifactorial as its barriers

An estimated 1.5 million people living the United States have lupus, and at least 5 million people across the globe have the condition. The disease is more common among people of African American and Hispanic descent.
Read More

Program aims to improve access, outcomes for high-risk patients

CHICAGO — A novel project designed to improve care quality and access for high-risk, high-cost lupus patients at a university medical center is reducing the outpatient no-show rate, hospitalization rate, and hospital length of stay.

Read More

Medicaid beneficiaries found poorly adherent to lupus medication

Adherence to a primary therapy for systemic lupus erythematosus (SLE) among Medicaid beneficiaries is low overall and even lower among some specific groups identified by sociodemographic factors or other variables, according to an analysis of a Medicaid database.

Read More

Diagnosing lupus: ANA testing comes under scrutiny

Researchers found further evidence about how tests for systemic lupus erythematosus (SLE) can fail to detect certain cases, adding to a growing discussion about how to best diagnose this condition.

Read More

Growing up with lupus carries huge emotional, physical toll

Growing up with lupus carries huge emotional, physical toll

Lupus presents in different ways in young people and requires evolving treatment strategies coupled with ongoing emotional support.

Read More

How essential are steroids to treating lupus nephritis?

In Toronto, kidney physician Joanne Bargman, MD, treats a young woman who has lupus nephritis and hates the steroids used to treat flares. The patient doesn’t want to take the vital corticosteroid drugs like prednisone that calm the immune system but can cause weight gain, acne and unwanted hair growth.

Read More